GILD - Gilead Sciences, Inc.
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.
What happened Gilead Sciences, Inc. (NASDAQ: GILD) said Chairman and CEO and director Daniel Patrick O'Day sold 15,000 shares on 2026-10-01. The stock went at prices from $147.72 to $148.63 a share, for about $2.22 million total. The filing leaves O'Day with 566,683 shares after the trade. The filing lists the stock as common stock
Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.
Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-nine research firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to
Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We also report on an experimental Gilead therapy showing great promise against a difficult-to-treat form of blood cancer, and an interesting new method for studying cells linked to age-related disorders.
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.
Envestnet Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,749,512 shares of the biopharmaceutical company's stock after selling 109,500 shares during the period. Envestnet Asset Management Inc. owned approximately
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around concerns that the initial Gilead-.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the.
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an “inflection point in value.”
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the [url="]Pan American Health Organization (PAHO)[/url] to accelerate access to twice